ClinicalTrials.gg
RecruitingNCT05814952Updated Apr 18, 2023

Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)

An interventional study of LX103 Injection in X-linked Retinoschisis, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to male participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Dec 2022, registered Apr 2023).
  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
6 Years and older
Sex
Male
01

Study summary

The goal of this study is to evaluate the safety and efficacy of LX103 treatment of X-linked retinoschisis. This study will enroll subjects aged ≥ 6 years old to receive a single unilateral intravitreal (IVT) injection of LX103 to evaluate its safety and efficacy.

02

Conditions studied

  • X-linked Retinoschisis

Browse trials for

03

In context

Retinoschisis

19 studies on the registry are indexed under Retinoschisis; 5 are open to participants now.

This study's planned enrollment of 12 is below the median of 19 across 12 interventional studies indexed under Retinoschisis.

Browse Retinoschisis studies →

Lead sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 182 studies on the registry; 108 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to sign the , and willing to attend follow-up visits.
  2. Male individual at least 6 years of age with a diagnosis of XLRS and documented mutations in the RS1 gene.
  3. The study eye must have a best-corrected E-ETDRS visual acuity letter score of less than or equal to 63.

Exclusion criteria

Exclusion Criteria:

  1. Any eye with disease that would interfere with the fundus examinations.
  2. The study eye is receiving topical carbonic anhydrase inhibitor, or has received topical carbonic anhydrase inhibitors in the past three months.
  3. The study eye has undergone intraocular surgery within six months prior to enrollment.
  4. Participant has uncontrolled hypertension or diabetes.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    LX103 Injection

    Potential doses: 5E10 vg, 0.1 mL/eye/dose (low dose) 1E11 vg, 0.05 mL/eye/dose (high dose)

    Genetic: LX103 Injection

Interventions

  • GeneticLX103 Injection

    Qualified subjects will receive a single unilateral intravitreal injection of LX103 at Day 0 in the trial.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Incidence of adverse events (AEs) within 24 weeks of LX103 intravitreal injection at different doses

    Time frame: 24 weeks

  2. Incidence of serious adverse events (SAEs)

    Incidence of serious adverse events (SAEs) within 24 weeks of LX103 intravitreal injection at different doses

    Time frame: 24 weeks

Secondary outcomes

  1. Mean change from baseline in BCVA (LogMAR) in the study eye

    ETDRS visual acuity charts will be used to assess BCVA

    Time frame: 24 weeks, 52 weeks

  2. Mean change from baseline in central subfield thickness (CST) in the study eye

    Mean change of CST measured using Optical Coherence Tomography (OCT)

    Time frame: 24 weeks, 52 weeks

  3. Change from baseline in Electroretinogram (ERG) parameters in the study eye

    Change in dark-adapted 3.0 B-wave amplitude (μV)

    Time frame: 24 weeks, 52 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Aug 2024, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2023
First posted
Apr 18, 2023
StartActual
Dec 13, 2022
Primary completionEst.
Aug 2024
CompletionEst.
Aug 2028
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05814952
Collaborators
Innostellar Biotherapeutics
Responsible party
Xiaodong Sun (PhD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Apr 18, 2023
Start date
Dec 13, 2022
Primary completion
Aug 2024 (estimated)
Completion
Aug 2028 (estimated)
Last update
Apr 18, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion